Premium
Transcatheter aortic valve replacement in patients with end‐stage renal disease: Is “better than nothing” good enough?
Author(s) -
Chiarito Mauro,
Mehran Roxana
Publication year - 2020
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.29341
Subject(s) - medicine , end stage renal disease , stenosis , aortic valve replacement , valve replacement , cardiology , aortic valve stenosis , population , observational study , concomitant , disease , surgery , environmental health
Key Points Patients with end‐stage renal disease (ESRD) have a three‐fold higher prevalence of aortic stenosis than patients with normal renal function, and are at increased risk of adverse events after surgical (SAVR) or transcatheter aortic valve replacement (TAVR). However, the optimal management of ESRD patients with concomitant aortic stenosis is still debated. This large observational, multicenter registry showed that in ESRD patients TAVR improves short term prognosis and reduces length and cost of hospital stay as compared with SAVR, although the rates of complications and mortality was still concerning. Specific efforts to refine the performance of TAVR in ESRD patients are urgently needed to improve outcome and quality of life in this growing population.